CIBC Private Wealth Group LLC Buys Shares of 5,668 Ascendis Pharma A/S (NASDAQ:ASND)

CIBC Private Wealth Group LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASNDFree Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 5,668 shares of the biotechnology company’s stock, valued at approximately $714,000.

Several other large investors have also modified their holdings of ASND. GAMMA Investing LLC purchased a new stake in Ascendis Pharma A/S in the 4th quarter valued at approximately $25,000. Quadrant Capital Group LLC lifted its position in shares of Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 91 shares during the last quarter. Legato Capital Management LLC acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter valued at $204,000. Finally, Certuity LLC purchased a new stake in Ascendis Pharma A/S during the 4th quarter worth about $270,000.

Ascendis Pharma A/S Stock Down 4.1 %

Shares of NASDAQ ASND opened at $131.48 on Tuesday. Ascendis Pharma A/S has a 52-week low of $85.08 and a 52-week high of $161.00. The firm has a fifty day moving average of $137.71 and a 200-day moving average of $135.07. The stock has a market capitalization of $7.66 billion, a PE ratio of -13.68 and a beta of 0.59.

Ascendis Pharma A/S (NASDAQ:ASNDGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($2.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.91). Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. The company had revenue of $103.11 million for the quarter, compared to analysts’ expectations of $85.72 million. Equities research analysts expect that Ascendis Pharma A/S will post -5.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ASND shares. Wells Fargo & Company raised their price target on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, May 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $173.00 price target on shares of Ascendis Pharma A/S in a research note on Wednesday, May 15th. Morgan Stanley lifted their price objective on Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an “equal weight” rating in a research report on Thursday, May 16th. Finally, Stifel Nicolaus began coverage on Ascendis Pharma A/S in a research report on Friday, May 31st. They set a “buy” rating and a $200.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $179.44.

Read Our Latest Stock Report on ASND

Ascendis Pharma A/S Profile

(Free Report)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Featured Stories

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.